Author: Himanshu Patni
24 November 2023
Nanotechnology offers the means to target therapies directly and selectively for cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. The increasing prevalence of cancer and advancements in treatment options are playing a significant role in boosting the cancer nanotechnology market in the United States. The rising prevalence of cancer is primarily attributed to rise in market in this region. For instance, in the US, an estimated 40 out of 100 men and 39 out of 100 women will develop cancer during their lifetime.Furthermore, advancements in the treatment of cancer, lead to improved outcomes for patients. US companies manufacture 45% to 50% of marketed nanomedicine products. The US Food and Drug Administration (FDA) approved the nanotechnology-enabled imaging agents and cancer drugs over a decade ago. FDA-approved nanomedicines include iron oxide nanoparticles for enhanced MRI imaging contrast and Abraxane, a nanoparticle formed by binding the serum protein albumin to the chemotherapy drug paclitaxel, and Doxil, a pegylated liposomal formulation of the chemotherapy drug docetaxel.
Access sample report (including graphs, charts, and figures) – https://univdatos.com/get-a-free-sample-form-php/?product_id=45185
Additionally, the Canadian government has been investing in cancer research and treatment programs, providing funding for clinical trials and research into new treatments. This has helped to drive innovation in the field and improve patient outcomes. Further, the investment and funds received from government bodies is also driving the market growth. For instance, Engineering researchers at McMaster University will be escalating efforts to develop these micro- and nanotechnology-based biosensors and imaging devices through the support of a recently announced $4.25 million grant from the Canada Foundation for Innovation.
Further, the North America Cancer Nanotechnology Market is expected to grow at a strong CAGR of 13.4% during the forecast period (2023-2030). In conclusion, the growth of the cancer nanotechnology market in North America is a result of a combination of factors, including the increasing prevalence of cancer, advancements in treatment options, increasing healthcare expenditure.
North America Cancer Nanotechnology Market Revenue (2020-2030)- USD bn
Based on type, the market is segmented into nanoparticles, nanofibers, nanorods, graphene, nanofluidic devices, and others. Among these nanoparticles have a significant share of the market This is because drug delivery devices and systems increased as nanoparticle drug formulations are vital in pulmonary drug delivery. The nanoparticles can deliver the normally insoluble drugs to local and distant tumor sites in a better way, thus reducing the systemic side effects generally associated with traditional drug therapies.
Based on application, the market is segmented into diagnostics, therapeutics, and theranostics. Among these, diagnostics has a high market share in 2022 and will dominate during the forecast period. This is due to the rise in the adoption of nanotechnology in medical diagnosis and imaging is increasing the market growth demand. In biomedical research, nanotechnology is widely used against COVID-19, as in numerous vaccinations that use nanoparticles as a treatment based on the encapsulation of the active ingredient of certain medications. Numerous nanosystems have been found to be better candidates for therapeutic purposes than conventional ones. Thus, this factor boosts market growth.
Based on the cancer type, the market is segmented into breast cancer, stomach cancer, lung cancer, and others. Among this breast cancer will attain a high market share during the forecast period. Breast cancer held more than 60% share in the market owing to the presence of wide range of nanotechnology for the management of breast cancer and the surge in the prevalence of breast cancer.
For a detailed analysis of the Global Cancer Nanotechnology Market browse through – https://univdatos.com/report/cancer-nanotechnology-market/
Global Cancer Nanotechnology Market Segmentation
Market Insight, by Type
· Nanoparticles
· Nanofibers
· Nanorods
· Graphene
· Nanofluidic Devices
· Others
Market Insights, by Application
· Diagnostics
· Therapeutics
· Theranostics
Market Insights, by Cancer Type
· Breast Cancer
· Stomach Cancer
· Lung Cancer
· Others
Market Insight, by Region
· North America Cancer Nanotechnology Market
o U.S.
o Canada
o Rest of North America
· Europe Cancer Nanotechnology Market
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
· Asia-Pacific Cancer Nanotechnology Market
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
· Rest of the World Cancer Nanotechnology Market
Top Company Profiles
· Johnson & Johnson
· GE Healthcare
· Combimatrix Corporation (Invitae Corporation)
· F. Hoffmann-La Roche
· Sigma-Tau Pharmaceuticals Inc.
· Merck and Company Inc.
· Pfizer, Inc.
· Nanosphere, Inc. (Luminex Corporation)
· Celgene Corporation
· Teva Pharmaceutical Industries
Get a call back
